LRRK2 Expression in Postmortem Brain
Research Grant, 2014
Mutations in LRRK2 are a major genetic cause of Parkinsonís disease. This study aims to determine what happens to the amount of LRRK2 protein in the brains of people with Parkinsonís disease.
The project will use standard techniques to measure the amount of LRRK2 in a large number of donor brains sourced throughout the world. We will determine if the amount of LRRK2 differs in Parkinsonís disease brain tissue compared to healthy control tissue over the course of Parkinsonís disease.
Relevance to Diagnosis/Treatment of Parkinsonís Disease:
Understanding the function of the LRRK2 protein has the potential to provide insight into the causes of Parkinsonís disease. Furthermore, LRRK2 itself may be a therapeutic target for the treatment of Parkinsonís disease. It is therefore important to understand how LRRK2 is behaving in brain tissue.
We aim to determine whether or not altered levels of LRRK2 protein contribute to the pathogenesis of Parkinsonís disease. The results will also provide information about the usefulness of LRRK2 as a therapeutic target for the disease.†
Signal Transduction and LRRK2 Biology Program Director at The Parkinson's Institute
Location: Sunnyvale, California, United States
Reader and Honorary Consultant in Neuropathology at University College London, Institute of Neurology
Location: London, United Kingdom
Professor of Neuroscience and NHMRC Senior Principal Research Fellow at University of New South Wales and Neuroscience Research Australia
Location: Sydney, Australia
Chairman, Department of Neurology and Bioresource Center (Brain Bank for Aging Research) at Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
Location: Tokyo, Japan
Senior Research Fellow at The University of Sydney
Location: Sydney, NSW, Australia